Study of QL1706 with short radiation and chemo for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment combining an immunotherapy drug (QL1706) with short-course radiation and chemotherapy for people with locally advanced rectal cancer that is microsatellite stable (MSS). The goal is to see if adding immunotherapy helps shrink tumors more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have been diagnosed with a type of rectal cancer that has not spread to other parts of the body.
- Your tumor is located within about 5 inches from the anus.
- Your cancer is MSS (microsatellite stable), which means it does not have a certain genetic instability.
- You have not had prior radiation, chemotherapy, immunotherapy, or targeted therapy for rectal cancer.
- You are in generally good health, able to perform daily activities with little or no help.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
This trial tests a combination of focused radiation therapy given quickly, along with chemotherapy, targeted drugs, and immunotherapy before surgery for locally advanced rectal cancer. The goal is to shrink the tumor and improve survival chances by treating the cancer aggressively before an operation.
This trial tests combining immunotherapy with standard chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to see if this approach can improve outcomes for patients whose tumors have certain genetic features (pMMR or MSS).
This trial tests whether combining short-course radiation with a chemotherapy regimen (CAPOX) and an immunotherapy drug (QL1706) can help treat rectal cancer that has spread to the liver. It is designed for patients who have not had any prior cancer treatment.
This trial tests a new combination of short-course radiation, a targeted therapy called fruquintinib, and an immunotherapy (PD-1 antibody) as a treatment before surgery for certain types of rectal cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests adding an immunotherapy drug (QL1706) to standard chemotherapy and radiation before surgery for low rectal cancer. The goal is to see if this combination can shrink tumors more effectively.
Hear when a new Locally Advanced Rectal Cancer (LARC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.